Business
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
ROCKVILLE, Md., May 8, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT)
About this update from Regenxbio Inc.
[{"type":"text","content":"ROCKVILLE, Md., May 8, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place in New Orleans, May 13 through 17, 2025. The presentations highlight REGENXBIO's leading end-to-end capabilities across research and early development, late-stage clinical development, and gene therapy manufacturing.\nPresentations include encore data from late-stage clinical trials of RGX-121 (clemidsogene lanparvovec) for the treatment of MPS II and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as preclinical research supporting the novel construct of RGX-202 with the C-Terminal domain, capsid discovery research, and RGX-202 manufacturing process development enabling industry-leading purity levels in Duchenne gene therapy.\nOral Presentations:Abstract Title: Development of a Commercial Manufacturing Process for RGX-202, a Systemically Delivered AAV for the Treatment of Duchenne Muscular DystrophyPresenter: Donald Startt, Executive Director, Process Development, REGENXBIOSession: AAV Vector Manufacturing: Process DevelopmentDate/Time: May 13, 1:30 p.m. CT\nAbstract Title: RGX-121 (clemidsogene lanparvovec): an Investigational AAV Gene Therapy for the Treatment of Neuronopathic Mucopolysaccharidosis Type IIPresenter: Olivier Danos, Ph.D., Executive Vice President, Chief Scientific Officer, REGENXBIOSession: CNS Gene Delivery for Metabolic Diseases: History and ChallengesDate/Time: May 14, 8:00 a.m. CT\nAbstract Title: RGX-202, an Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy: Interim Clinical DataPresenter: Olivier Danos, Ph.D., Executive Vice President, Chief Scientific Officer, REGENXBIOSession: Gene Therapy Trials: In-Vivo Gene Therapy ModificationDate/Time: May 16, 3:45 p.m. CT\nPoster Presentations:Abstract Title: Impact of Sample Collection Container Material, Hold Time, and Storage Temperature on Adeno-Associated Virus Endotoxin TestingPresenter: Amanda Zhang, Associate Director Vectore Core, REGENXBIOSession: Tuesday Poster SessionDate/Time: May 13, 6:00 p.m. CT\nAbstract Title: AAV-Expressed Microdystrophin Containing Extended C-Terminus Improves Muscle Function and Protects Against Injury in a Mouse Model of Duchenne Muscular DystrophyPresenter: Benjamin Heithoff, Ph.D., Scienti...